MCID: CNN004
MIFTS: 42

Connective Tissue Cancer

Categories: Cancer diseases

Aliases & Classifications for Connective Tissue Cancer

MalaCards integrated aliases for Connective Tissue Cancer:

Name: Connective Tissue Cancer 12 14
Neoplasms, Connective Tissue 42 69
Neoplasm of Connective Tissues 12
Tumour of Connective Tissue 12
Connective Tissue Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:201
MeSH 42 D009372
SNOMED-CT 64 126598008 254821003
UMLS 69 C0027656

Summaries for Connective Tissue Cancer

Disease Ontology : 12 A musculoskeletal system cancer that is located in connective tissue.

MalaCards based summary : Connective Tissue Cancer, also known as neoplasms, connective tissue, is related to connective tissue benign neoplasm and spindle cell sarcoma. An important gene associated with Connective Tissue Cancer is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are PI3K-Akt signaling pathway and MAPK Signaling: Mitogen Stimulation Pathway. The drugs Aminolevulinic acid and Polidocanol have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and t cells, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and pigmentation

Related Diseases for Connective Tissue Cancer

Diseases in the Connective Tissue Cancer family:

Connective Tissue Benign Neoplasm

Diseases related to Connective Tissue Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 101)
id Related Disease Score Top Affiliating Genes
1 connective tissue benign neoplasm 32.9 CD34 CD68 EWSR1
2 spindle cell sarcoma 32.1 CDK4 EWSR1 FUS MDM2 TP53
3 pediculus humanus capitis infestation 11.0 SSX1 SSX2B
4 ring chromosome 8 11.0 COL1A1 PDGFB
5 vitreous syneresis 11.0 CD99 EWSR1
6 liposarcoma 11.0 EWSR1 MDM2
7 acute cholinergic dysautonomia 11.0 MDM2 TP53
8 adult malignant hemangiopericytoma 11.0 CD34 SSX1
9 large cell carcinoma 11.0 SSX1 SSX2B
10 sphenoid sinus schneiderian papilloma 11.0 CD34 CD99
11 multiple mucosal neuroma 11.0 CD34 TP53
12 sparse hair ptosis mental retardation 10.9 EWSR1 MDM2 TP53
13 cervical adenoma malignum 10.9 CD34 EWSR1
14 rnase t2-deficient leukoencephalopathy 10.9 CDK4 MDM2 TP53
15 primary pulmonary lymphoma 10.9 CDK4 MDM2
16 benallegue lacete syndrome 10.9 COL1A1 PDGFB
17 cellular ependymoma 10.9 EWSR1 SS18 SSX1
18 breast epithelioid hemangioma 10.9 CDK4 MDM2 TP53
19 secondary pulmonary hemosiderosis 10.9 CDK4 MDM2 TP53
20 ascaridiasis 10.9 CDK4 MDM2 TP53
21 extrahepatic biliary papillomatosis 10.9 CD34 CD68
22 enamel hypoplasia cataract hydrocephaly 10.9 CDK4 MDM2 TP53
23 epidural neoplasm 10.9 CDK4 MDM2
24 skin lipoma 10.9 CD34 CDK4 MDM2
25 coronary aneurysm 10.9 CD34 CDK4 MDM2
26 sarcosinemia 10.9 CDK4 FUS MDM2
27 spondyloepimetaphyseal dysplasia, isidor type 10.9 CD99 EWSR1 FUS
28 filamentary keratitis 10.9 CD34 CD68
29 reactive arthritis 10.9 CD68 CDK4 MDM2
30 peritoneal benign neoplasm 10.9 CD34 TP53 TRPV1
31 inner ear cancer 10.9 CD34 CD68
32 c-p angle neurinoma 10.9 CD34 MDM2 TP53
33 rhabdomyosarcoma 2, alveolar 10.9 CDK4 EWSR1 MDM2
34 unilateral retinoblastoma 10.9 CDK4 MDM2 TP53
35 pharynx cancer 10.9 CDK4 MDM2 TP53
36 biliary dyskinesia 10.9 CD68 MDM2 TP53
37 juxtacortical osteosarcoma 10.9 CD99 EWSR1 PDGFB
38 cystic lymphangioma 10.9 CDK4 MDM2 TP53
39 fibrosarcoma of bone 10.9 CD34 CREB3L2 EWSR1
40 ossifying fibromyxoid tumor 10.9 CD34 CDK4 TP53
41 cowper gland carcinoma 10.9 CD34 CREB3L2 TP53
42 post-surgical hypoinsulinemia 10.8 CDK4 MDM2 TP53
43 papillary serous adenocarcinoma 10.8 CD34 SS18 SSX2B
44 sparse hair-short stature-skin anomalies syndrome 10.8 CREB3L2 FUS
45 fallopian tube squamous cell carcinoma 10.8 CD34 CD68 TP53
46 extraosseous osteosarcoma 10.8 CDK4 CREB3L2 MDM2
47 adenosarcoma 10.8 CDK4 MDM2 TP53
48 tropical spastic paraparesis 10.8 CD34 CD68
49 testicular spermatocytic seminoma 10.8 CD34 CD68
50 heel spur 10.8 CD34 EWSR1

Graphical network of the top 20 diseases related to Connective Tissue Cancer:



Diseases related to Connective Tissue Cancer

Symptoms & Phenotypes for Connective Tissue Cancer

GenomeRNAi Phenotypes related to Connective Tissue Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.64 TLE1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.64 FUS
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.64 CDK4
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.64 SSX2B
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.64 SSX2B
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.64 EWSR1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.64 SSX1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.64 EWSR1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.64 FUS
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.64 CDK4 EWSR1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.64 TLE1 FUS
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.64 TLE1 CDK4 EWSR1 FUS SSX1 SSX2B
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.64 EWSR1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.64 EWSR1

MGI Mouse Phenotypes related to Connective Tissue Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 pigmentation MP:0001186 9.35 CDK4 COL1A1 MDM2 PDGFB TP53
2 renal/urinary system MP:0005367 9.17 CAMKMT CDK4 COL1A1 MDM2 PDGFB TP53

Drugs & Therapeutics for Connective Tissue Cancer

Drugs for Connective Tissue Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 636)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 2 106-60-5 137
2
Polidocanol Approved Phase 4 9002-92-0
3
Adalimumab Approved Phase 4,Phase 2,Phase 3,Phase 1 331731-18-1 16219006
4
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2 428863-50-7
5
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 185243-69-0
6
Infliximab Approved Phase 4,Phase 3,Phase 2 170277-31-3
7
Desogestrel Approved Phase 4 54024-22-5 40973
8
Dienogest Approved Phase 4 65928-58-7
9
Goserelin Approved Phase 4 65807-02-5 47725 5311128
10
Nandrolone Approved, Experimental, Illicit Phase 4 434-22-0, 62-90-8 9904 229455
11
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
12
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
13
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
14
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
15
Tamoxifen Approved Phase 4,Phase 2,Phase 1 10540-29-1 2733526
16
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
17
Calcium Carbonate Approved Phase 4,Phase 3 471-34-1
18
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
19
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
20
Etoposide Approved Phase 4,Phase 3,Phase 1,Phase 2 33419-42-0 36462
21
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
22
Mechlorethamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-75-2 4033
23
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
24
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
25
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
26
Heparin Approved, Investigational Phase 4,Phase 1 9005-49-6 772 46507594
27
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
28
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
29
Ethanol Approved Phase 4 64-17-5 702
30
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
31
Morphine Approved, Investigational Phase 4,Phase 1,Phase 2 57-27-2 5288826
32
Abatacept Approved Phase 4,Phase 3,Phase 2,Phase 1 332348-12-6 10237
33
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
34
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
35
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
36
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
37
Diphenhydramine Approved Phase 4,Phase 2 58-73-1, 147-24-0 3100
38
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
39
Promethazine Approved Phase 4,Phase 2 60-87-7 4927
40
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
41
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
42
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
43
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
44
Zinc oxide Approved Phase 4,Phase 2 1314-13-2
45
Tofacitinib Approved, Investigational Phase 4,Phase 3,Phase 2 477600-75-2
46
Progesterone Approved, Vet_approved Phase 4,Phase 2 57-83-0 5994
47
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2 53714-56-0 3911 657181
48
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
49
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2 118-42-3 3652
50
Sulfasalazine Approved Phase 4,Phase 3 599-79-1 5353980 5359476

Interventional clinical trials:

(show top 50) (show all 1578)

id Name Status NCT ID Phase Drugs
1 Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Unknown status NCT00313066 Phase 4
2 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
3 An Assessment of Intra-lesional 3% Polidocanol Solution in the Treatment of Digital Myxoid Cyst Unknown status NCT02154789 Phase 4 polidocanol
4 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
5 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4 Human papilloma virus vaccine (cervarix)
6 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
7 High Intensity Focused Ultrasound Ablation Virus Myomectomy to Treat Uterine Fibroids Unknown status NCT01239641 Phase 4
8 Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
9 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
10 Sleep Quality After Stellate-ganglion Block of Patients Undergoing Breast Cancer Operation Completed NCT02651519 Phase 4 0.25% ropivacaine hydrochloride;saline
11 Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor Completed NCT00793871 Phase 4 Sunitinib Malate (SU011248)
12 Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate Completed NCT00510354 Phase 4 Imatinib mesylate
13 Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) Completed NCT00171977 Phase 4 Imatinib Mesylate
14 Physical Characteristics of Retrieved Massive Allografts Completed NCT00160758 Phase 4
15 A Study to Determine the Number of Participants With Rheumatoid Arthritis (RA) Who Meet the Requirements for Treatment With Anti‐Tumor Necrosis Factor α (TNFα) in a General Hospital Setting in Korea Completed NCT01294722 Phase 4
16 A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
17 HLA Sensitization Following Major Cortical Allograft Bone Procedures Completed NCT00160719 Phase 4
18 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
19 Anti-TNF Agents for the Treatment of Rheumatoid Arthritis Completed NCT00837434 Phase 4 Etanercept;Adalimumab
20 Intravenous or Intra-abdominal Local Anesthetics for Postoperative Pain Management. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
21 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer Completed NCT00999921 Phase 4 Tamoxifen;Evening Primrose Oil
22 Humira in Rheumatoid Arthritis - Do Bone Erosions Heal? Completed NCT00696059 Phase 4 Adalimumab (Humira)
23 SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. Completed NCT01295151 Phase 4 Etanercept;Abatacept;Adalimumab;Certolizumab Pegol;Infliximab;Golimumab
24 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy Completed NCT02196480 Phase 4
25 Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis Completed NCT00420927 Phase 4 methotrexate
26 A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study Completed NCT02049112 Phase 4
27 Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients Completed NCT01022905 Phase 4
28 Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice Completed NCT01692899 Phase 4
29 A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA) Completed NCT01163747 Phase 4 methotrexate
30 A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis Completed NCT01382940 Phase 4 rituximab;methotrexate;methylprednisolone;acetaminophen;antihistamine
31 A Long-term Safety Study of Infliximab (Remicade) Completed NCT00261976 Phase 4 Infliximab (Remicade)
32 A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis Completed NCT01089023 Phase 4 tocilizumab [RoActemra/Actemra]
33 Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial Completed NCT01400516 Phase 4 Teriparatide;calcium citrate;Vitamin D;TNF antagonist
34 Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA) Completed NCT01382160 Phase 4
35 Acute Effect of Resistance Training in Inflammatory Markers in Women With Rheumatoid Arthritis Completed NCT02401958 Phase 4
36 Study Evaluating the Efficacy of Enbrel (Etanercept) in Subjects in Japan Completed NCT00503503 Phase 4 Enbrel (etanercept)
37 Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan Completed NCT00503139 Phase 4 Enbrel (etanercept)
38 Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA Completed NCT00792233 Phase 4
39 A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs. Completed NCT01195272 Phase 4 tocilizumab [RoActemra/Actemra]
40 Imatinib in KIT-negative Systemic Mastocytosis Completed NCT01297777 Phase 4 Imatinib Mesylate
41 Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis Completed NCT01593332 Phase 4 Rituximab;Rituximab
42 Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators Completed NCT00743080 Phase 4
43 Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
44 Fibroids in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4 Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
45 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization Completed NCT02293447 Phase 4 Lidocaine per-embolization;Lidocaine post-embolization
46 Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis Recruiting NCT02092467 Phase 4 tofacitinib;tofacitinib
47 Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis Recruiting NCT01793519 Phase 4 Etanercept;Infliximab;Adalimumab;Placebo
48 The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib Recruiting NCT02800330 Phase 4 Esomeprazole 40mg concomitantly;Esomeprazole 40mg before;Regorafenib 160mg or 120mg
49 RHYTHM (Formerly Escape II Myocardium) Recruiting NCT01548768 Phase 4 TNF inhibitors;DMARDs
50 Ulipristal Use in Chinese Population Recruiting NCT02825719 Phase 4 Ulipristal acetate;Ferrous sulphate;Tranexamic Acid

Search NIH Clinical Center for Connective Tissue Cancer

Cochrane evidence based reviews: neoplasms, connective tissue

Genetic Tests for Connective Tissue Cancer

Anatomical Context for Connective Tissue Cancer

MalaCards organs/tissues related to Connective Tissue Cancer:

39
Bone, Lung, T Cells, Bone Marrow, Kidney, Testes, Myeloid

Publications for Connective Tissue Cancer

Articles related to Connective Tissue Cancer:

id Title Authors Year
1
Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET). ( 23446092 )
2013
2
Long-term effects of connective tissue cancer treatment. ( 15346055 )
2004

Variations for Connective Tissue Cancer

Expression for Connective Tissue Cancer

Search GEO for disease gene expression data for Connective Tissue Cancer.

Pathways for Connective Tissue Cancer

GO Terms for Connective Tissue Cancer

Biological processes related to Connective Tissue Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.55 CD34 MDM2 PDGFB TLE1 TP53
2 cellular response to growth factor stimulus GO:0071363 9.43 MDM2 PDGFB TRPV1
3 response to hyperoxia GO:0055093 9.4 CDK4 COL1A1
4 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.37 MDM2 PDGFB
5 cellular response to alkaloid GO:0071312 9.32 MDM2 TRPV1
6 paracrine signaling GO:0038001 8.96 CD34 PDGFB
7 cellular response to actinomycin D GO:0072717 8.62 MDM2 TP53

Molecular functions related to Connective Tissue Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.23 COL1A1 EWSR1 FUS MDM2 PDGFB TLE1
2 platelet-derived growth factor binding GO:0048407 8.96 COL1A1 PDGFB

Sources for Connective Tissue Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....